CLINICAL COURSE OF PARKINSON'S DISEASE IN PATIENTS AFTER COVID-19
Keywords:
Coronavirus, Parkinson's disease, motor and non-motor disordersAbstract
The aim of our study was to study the course of Parkinson`s disease in patients who had undergone coronavirus infection. The comparative analysis of motor and non-motor disorders in Parkinson's disease is planned. Currently, the study of the effect of coronavirus on the nervous system, including the central nervous system, is the most urgent.
References
Иллориошкин С.Н. Болезнь Паркинсона в эпоху пандемии Covid-19 // нервные болезни. 2021. - №4.- С.11-18.
Иллариошкин С.Н., Федотова Е.Ю., Селиверстов Ю.А. Современные высокотехнологичные методы лечения болезни Паркинсона. В кн.: Болезни мозга – медицинские и социальные аспекты. Под ред. Гусева Е.И., Гехт А.Б. М.: Буки-Веди; 2016: 543-52.
Левин О.С., Федорова Н.В. Болезнь Паркинсона. 4-е изд. М.: МЕДпресс-информ; 2014. 384 с.
Полещук В.В., Иллариошкин С.Н. Амантадин при болезни Паркинсона. Медицинский совет 2018;9:34-8.
Левин О.С. Феноменология и лечение декомпенсации болезни Паркинсона. Неврологический журнал 2007;1:8-15.
Рахимбаева Гульнора Саттаровна, Шодиев Улуғбек Дониёр ўғли. Постковид цeрeбро-астeник синдром: диагностик йондашувларни оптималлаштириш, долзарб жихатлари // Журнал неврологии и нейрохирургических исследований №2.2021. 6-10 бет.
Туйчиев Л.Н., Рахимбаева Г.С., Газиева Ш.Р., Атаниязов М.К. Новая коронавирусная ин¬фекция и постковидные неврологиче¬ские последствия заболевания // Вестник ТМА № 2, 2021. 45-50 стр.
Атаниязов Махсуджан Камаладдинович, Рахимбаева Гульнора Саттаровна, Газиева Шохида Рустамовна. Характерные особенности инсульта при covid-19 // Журнал неврологии и нейрохирургических исследований №2.2021.14-17 стр.
Alipoor SD, Mortaz E, Varahram M, Garssen J, Adcock IM. The immunopathogenesis of neuroinvasive lesions of SARS-CoV-2 infection in COVID-19 patients. Frontiers in Neurology 2021 Jul;12:697079.
Artusi CA, Romagnolo A, Ledda C, Zibetti M, Rizzone MG, Montanaro E, Bozzali M, Lopiano L. COVID-19 and Parkinson’s disease: what do we know so far? Journal of Parkinson’s Disease 2021;11(2):445-54.
Beauchamp LC, Finkelstein DI, Bush AI, Evans AH, Barnham KJ. Parkinsonism as a third wave of the COVID-19 pandemic? Journal of Parkinson’s Disease 2020;10(4):1343-53.
Boesl F, Audebert H, Endres M, Prüss H, Franke C. A neurological outpatient clinic for patients with post-COVID-19 syndrome – a report on the clinical presentations of the first 100 patients. Frontiers in Neurology 2021 Sep;12:738405.
Brundin P, Nath A, Beckman JD. Is COVID-19 a perfect storm for Parkinson’s disease? Trends in Neurosciences 2020 Dec;43(12):931-3.
Cohen ME, Eichel R, Steiner-Birmanns B, Janah A, Ioshpa M, Bar-Shalom R, Paul JJ, Gaber H, Skrahina V, Bornstein NM, Yahalom G. A case of probable Parkinson’s disease after SARS-CoV-2 infection. The Lancet. Neurology 2020 Oct;19(10):804-5.
Chaudhry ZL, Klenja D, Janjua N, Cami-Kobeci G, Ahmed BY. COVID-19 and Parkinson’s disease: shared inflammatory pathways under oxidative stress. Brain Sciences 2020 Oct;10(11):807.
D. Sulzer, A. Antonini, V. Leta, A. Nordvig, R.J. Smeyne, J.E. Goldman, O. Al-Dalahmah, L. Zecca, A. Sette, L. Bubacco, O. Meucci, E. Moro, A.S. Harms, Y. Xu, S. Fahn, K. Ray Chaudhur COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside NPJ Parkinsons Dis. (2020), p. 6, 10.1038/s41531-020-00123-0
Faber I, Brandão PRP, Menegatti F, de Carvalho Bispo DD, Maluf FB, Cardoso F. Coronavirus disease 2019 and parkinsonism: a non-post-encephalitic case. Movement Disorders 2020 Oct;35(10):1721-2.
Fanciulli A., Habek M., Carneiro D. et al. COVID-19: statement by the Autonomic nervous system disorders Scientific Panel. April 17, 2020. Available at: https://www.eanpages.org/2020/04/17/covid-19-statement-by-the-autonomic-nervous-system-disorders-scientific-panel.
Fearon C, Fasano А. Parkinson’s disease and the COVID-19 pandemic. Journal of Parkinson’s Disease 2021;11(2):431-44.
Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Multiple Sclerosis and Related Disorders 2020 Jul; 42:102163.
Jin H., Hong C., Chen S. et al. Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. Stroke & Vascular Neurology 2020. DOI:10.1136/svn-2020-000382.
Khodjieva D.T., Khaydarov N.K., Kazakov B.Sh., Khaydarova D.K. Clinical and neurological factors in the formation of an individual predisposition to COVID-associated ischemic stroke. European Journal of Molecular & Clinical Medicine - 2020.
Khaydarova D.K., Samadov A.U. Current issues in the development of neuroprotective therapy in ischemic stroke. Web of Scientist: International Scientific Research Journal 2021, 6-10.
Khodjieva D.T., Safarov K.K. A Study of Neuropsychological Symptomatology and Its Clinical Features in Patients with COVID-19. American Journal of Medicine and Medical Sciences 2021, 11(2): 126-129
Stoessl A.J., Bhatia K.P., Merello M. Movement Disorders in the World of COVID‐19. Movement Disorders [published online ahead of print, 2020 Apr 6]. PMID: 32250468. DOI: 10.1002/mds.28069.
Wang T., Du Z., Zhu F. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 2020 Mar 21; 395(10228): e52. PMID: 32171074. DOI: 10.1016/S0140-6736(20)30558-4.
